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Summary 
Antithrombotic medications reduce thrombosis but increase bleeding. Identification of ST-
elevation myocardial infarction (STEMI) patients at risk of recurrent thrombosis could allow 
targeted treatment with potent antithrombotic medications, with less potent agents in 
others, to reduce bleeding. Conventional platelet function tests assess platelet reactivity only, 
yet there is increasing evidence that endogenous thrombolytic potential determines outcome 
following thrombus initiation. We investigated whether assessing both platelet reactivity and 
endogenous thrombolysis, could identify STEMI patients at high-risk of recurrent thrombotic 
events. Thrombotic status was assessed in STEMI patients, before and after primary 
percutaneous coronary intervention (PPCI), at discharge and at 30 days; with 12 months’ 
follow-up. The time to form an occlusive thrombus under high shear (occlusion time, OT), and 
time to restore flow by endogenous thrombolysis (lysis time, LT) was measured using the 
point-of-care Global Thrombosis Test (GTT) in the cardiac catheterisation laboratory. 
Impaired endogenous thrombolysis (prolonged LT≥3000s), seen in 13% patients pre-PPCI, was 
related to major adverse cardiac events, MACE (HR:3.31, 95%CI:1.02-10.78, p=0.045), driven 
by cardiovascular death (HR:4.17, 95%CI:0.99-17.51, p=0.05). Enhanced (rapid) endogenous 
thrombolysis (LT<1000s) was associated with spontaneous reperfusion, ST-segment 
resolution and Thrombolysis In Myocardial Infarction 3 flow pre-PPCI. Baseline OT was shorter 
in those with MACE (especially recurrent myocardial infarction and stroke) than those without 
(253±150s vs. 354±134s, p=0.017). Endogenous thrombolysis, when impaired, is associated 
with increased cardiovascular risk, and when enhanced, with spontaneous reperfusion. 
Endogenous thrombolysis may be a novel target for pharmacological intervention, and allow 
targeting of potent antithrombotic medications to high-risk patients.  
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Abbreviations 
ACS = acute coronary syndrome 
CVD = cardiovascular death 
GPI = glycoprotein IIb/IIIa inhibitors 
GTT = global thrombosis test 
LT = lysis time 
MACE = major adverse cardiovascular events  
MI = myocardial infarction 
NOACs = non-vitamin K antagonist oral anticoagulants 
OT = occlusion time 
PFTs = platelet function tests 
PPCI = primary percutaneous coronary intervention 
STEMI = ST-elevation myocardial infarction 
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Introduction 
Thrombotic occlusion of a coronary artery upon a background of atherosclerotic plaque 
rupture is considered the ultimate and key step in the pathogenesis of myocardial infarction 
(MI) (1). The emergency treatment of ST-elevation myocardial infarction (STEMI) is therefore 
two-pronged; namely, the pharmacological treatment and prevention of recurrent 
thrombosis (through antithrombotic and antiplatelet medications), and the mechanical relief 
of the atherosclerotic stenosis through primary percutaneous coronary intervention (PPCI). 
Even after mechanical relief of obstruction, there are many patients in whom there is failure 
to establish Thrombolysis in Myocardial Infarction (TIMI) 3 flow and a persistent pro-
thrombotic state contributes to ongoing microvascular thrombosis and extension of 
infarction. Introduction of increasingly potent antithrombotic and antiplatelet agents has 
reduced the risk of recurrent thrombosis. Yet despite such treatment, some 10 to 15% of MI 
patients go on to have a major adverse cardiac event (MACE) after the index event, which is 
due predominantly to thrombotic complications (2-5). Contemporary, newer antithrombotic 
and antiplatelet agents, whilst reducing recurrent thrombosis, have significantly increased the 
risk of bleeding (5-8). Identification of individuals at high-risk of future thrombotic 
complications would be highly desirable, since this group could be targeted with more potent 
antithrombotic medications, allowing perhaps the use of less potent agents (thereby reducing 
bleeding risk) in lower risk groups.  
Although many tests of platelet function tests (PFTs) are available, favourably modifying the 
results of PFTs through pharmacological modulation has not translated into a reduction in 
adverse thrombotic events. This may be due to intrinsic limitations of PFTs which differ from 
the in vivo situation (9), using citrated blood and measuring the response of platelets to only 
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specific agonists (10), which prevents assessment of thrombin generated by activated 
platelets or the effect of high shear (10), and importantly, spontaneous (endogenous) 
thrombolytic activity is not assessed. The innate ability of blood to induce lysis of a formed 
thrombus is an important defence mechanism against lasting arterial occlusion. 
Understandably, MI has been considered a result of the failure of timely spontaneous 
thrombolysis (11). The ideal test of thrombotic status should, in addition to assessing platelet 
reactivity, also measure the endogenous thrombolytic activity. Global assays, simultaneously 
assessing proaggregatory and fibrinolytic pathways, could play a role in risk stratification and 
in identifying impaired fibrinolysis as a potential target for pharmacological modulation (12). 
The Global Thrombosis Test (GTT) (Thromboquest Ltd., London, UK), is a highly physiological, 
automated point-of-care test that assesses platelet reactivity, coagulation (thrombin 
generation) and endogenous thrombolysis from a native, non-anticoagulated blood sample. 
Impaired endogenous thrombolysis, as assessed by the GTT, has been shown to predict MACE 
in patients with non ST-elevation MI (13), and in patients with end-stage renal disease (14). 
As this test is performed from native (non-anticoagulated) blood, and assesses global 
thrombosis and thrombolysis, it is genuinely different from other PFTs which employ citrate-
anticoagulated blood and cannot assess thrombolysis (10). We aimed to identify patients with 
STEMI undergoing PPCI who, despite dual antiplatelet medication, remain at risk of 
thrombotic complications and MACE, due to their inability to dissolve thrombus, namely 
impaired endogenous thrombolysis. 
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Materials and Methods 
Study design and population 
This prospective study was approved by the local research ethics committee. Consecutive 
eligible patients presenting with STEMI for emergency angiography with a view to PPCI, 
between the hours of 8 a.m. and 6 p.m. Monday-Friday, over the course of a year, were 
enrolled after obtaining informed consent. We included adults (≥18 years) with a presumed 
diagnosis of STEMI based on clinical presentation and ECG criteria (namely: new ST-elevation 
at the J point in at least 2 contiguous leads of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.15 mV) 
in women in leads V2–V3 and/or of ≥1 mm (0.1 mV) in other contiguous chest leads or the 
limb leads, or ST-depression in ≥2 precordial leads (V1–V4), or new or presumably new left 
bundle branch block (LBBB) in patients with clinical suspicion of ongoing myocardial ischaemia 
(15, 16)). All patients had received a loading dose of aspirin 300mg and clopidogrel 600mg in 
the ambulance or in the emergency department upon diagnosis of STEMI, within the 
preceding 20-60 min, in line with current local standard of care. The exclusion criteria listed 
in Table 1 were applied. Clinical characteristics of patients are shown in Tables 2 and 3. 
Unfractionated heparin (UFH) was given at a dose of 70 to 100 units per kilogram immediately 
before PPCI. Use of the glycoprotein IIb/IIIa inhibitor (GPI) abciximab (Reopro, Eli Lilly, 
Indianapolis, Indiana, USA) or bivalirudin (Angiomax, The Medicines Company, Parsippany, 
NJ, USA) was allowed at the operator’s discretion, in conjunction with UFH. Decisions 
regarding access site, thrombus aspiration, and stent type were left to physician preference. 
Procedural characteristics are shown in Table 4. All patients received dual antiplatelet 
medication for 12 months as part of local protocol. 
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Blood sampling 
Blood samples for thrombotic status were taken from all consented patients at 4 time points: 
1) baseline upon admission (after loading with dual antiplatelet therapy, DAPT), through the 
arterial sheath, prior to heparin or GPI administration and before PPCI, 2) approximately 30-
60 min after the administration of abciximab (if used), 3) at clinical stabilisation, just prior to 
hospital discharge, and 4) at 30 days’ follow-up. Fasting was not required.  
The first 2 time-point blood samples were taken from a 6-F radial or femoral sheath using a 
2-syringe technique. For the initial sample, the sheaths were only ever flushed with normal 
saline (and not heparinised saline) prior to sampling. The third and fourth samples were taken 
from an antecubital vein using an 18-G butterfly cannula also using a 2-syringe technique, 
taking care to avoid prolonged tourniquet time. The two syringe technique involved using the 
first 5 ml blood for routine blood tests and using the second 5 ml for assessment of thrombotic 
status. 
 
Assessment of global thrombotic status 
The Global Thrombosis Test (GTT) (Thromboquest Ltd., London, UK), an automated point-of-
care test, was used to assess both platelet reactivity and endogenous thrombolysis from a 
native, non-anticoagulated blood sample. The instrument has 4 independent measuring 
channels, and was positioned in the cardiac catheterisation laboratory. After blood sample 
was obtained, it was introduced into the disposable GTT cartridge, within 15 seconds of 
withdrawal and the automated measurement begun. The instrument assesses the time taken 
to form an occlusive thrombus under high shear stress (occlusion time, OT), and the time 
required to restore flow through endogenous thrombolysis (lysis time, LT). The principle of 
the GTT has previously been described in detail (13, 17). In brief, blood flows under high shear 
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conditions through narrow gaps inside the conical tube where thrombus formation occurs 
and the instrument measures the time (d) between 2 consecutive blood drops downstream 
of this. This time interval increases gradually as flow slows down and at an arbitrary point (d 
≥15s, before reaching complete occlusion), the end point of the measurement is displayed 
(occlusion time [OT], in seconds). Restart of blood flow after occlusion is due to spontaneous 
thrombolysis (lysis time [LT], in seconds). If lysis does not occur until >6,000s (LT cut-off time), 
“no lysis” is displayed and recorded. The coefficient of variation (cv) was assessed by testing 
a cohort of 10 stable patients on 2 occasions, 48 hours apart.  
 
ECG and Angiographic Analyses 
ECG and angiographic analyses were performed by two investigators blinded to clinical 
characteristics and outcome. Standard 12-lead ECGs were obtained on arrival in the cath lab 
and compared to that at baseline presentation (in ambulance or emergency department). All 
ECGs were analyzed using a hand-held caliper. The ST-segment was measured 20 ms after the 
J point, and the sum of ST deviation was measured as previously described (18). The percent 
resolution of ST deviation from baseline to arrival was calculated, and categorized using 
Schröder’s 3-component definition: complete (≥70%), partial (30% to 70%) and no (≤30%) ST 
resolution (18). Flow in the infarct-related artery was reported using the TIMI flow grading 
system and patency defined as TIMI grade 2 or 3 flow. 
 
Data collection and follow-up 
Patients were recruited during their index admission and their case notes and electronic 
records were examined, to allow contemporaneous completion of study-specific case record 
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forms. Patients were followed up at 30 days in person, and at 6 months and 1 year by 
telephonic follow up, for the occurrence of MACE, defined as the composite of cardiovascular 
death (CVD), nonfatal MI or stroke. The secondary endpoint was major bleeding. For all 
endpoints, source documents were obtained and diagnosis verified by 2 independent 
clinicians blinded to the GTT results. The end points of the study were as follows: CVD, 
recurrent non-fatal MI, stroke, and major bleeding, classified as type 3-5 according to the 
Bleeding Academic Research Consortium (BARC) definition (19). For definitions of endpoint 
events, please see Supplement 1. 
 
Statistical analysis 
A clinical trial assessing whether LT is a predictor of MACE in STEMI, based on an effect size 
(HR) of 2.5 (13), assuming a MACE rate of 10% and an attrition rate of 10% over the follow-up 
period, would require about 500 patients to achieve 80% power. Based on previous published 
guidance (20), a pilot study sample should include at least 10% of the sample projected for 
the larger study. We opted for 17% (85 patients) to allow for suitable numbers for the analysis. 
Paired and unpaired t tests were used for comparison of normally distributed and Mann-
Whitney U test used for non-normally distributed variables. Where necessary, log 
transformations were employed. Dichotomous variables were compared using chi-square 
test with continuity correction or Fisher's exact test, as appropriate. Correlations were 
analysed using Spearman's rank test. The OT and LT at baseline were related to the OT and LT 
at other time points. The OT and LT at the 4 time points were separately related to study end 
points of MACE or major bleeding. Separate analysis was used to compare the OT and LT of 
patients who had spontaneous coronary reperfusion to those who did not. Simple regression 
was used to examine the relationship between baseline OT and LT and pain to balloon time. 
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Ability of the test to discriminate between patients with and without MACE was evaluated by 
receiver-operating characteristic (ROC) curve analysis. Kaplan-Meier survival methods with 
log-rank tests were used. In addition, to investigate the relationship between increasing LT 
and MACE, univariate Cox proportional hazard regression was performed on LT. Univariate 
and multivariate hazard regression models of Cox were used, respectively, to identify risk 
factors for clinical end points and to adjust for potential confounders that were associated 
with clinical end points on univariate analysis. Net reclassification improvement (NRI) was 
used to assess the added predictive ability of LT ≥3,000 for MACE. Tests were two-sided, and 
significance was fixed at 0.05 level. Analyses were performed with Stata V.11.2 (StataCorp, 
College Station, Texas, USA).  
  
Results 
Out of 85 eligible patients, 2 patients met one or more exclusion criteria, and 1 patient 
declined consent. The clinical characteristics are shown in Tables 2 and 3. Angiographic, 
procedural and echocardiographic characteristics are shown in Table 4. The coefficient of 
variation (cv) was 8% for OT and 10% for LT. There was no relationship between baseline OT 
(r=0.03, p=0.592) or baseline LT (r=0.71, p= 0.283) and the time of blood sampling. 
 
Distribution and change in occlusion time 
Baseline OT was normally distributed and OT at the 4 sampling time points is shown in Figure 
1. OT was markedly prolonged after GPI/UFH treatment (mean±SD; 743±157s vs. 330±136s, 
p=0.00001) and after bivalirudin/UFH (707±121s vs. 381±97s, p=0.0004) compared to 
baseline, and remained prolonged at hospital discharge (536±195s vs. 330±136s, p=0.00001) 
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and at 30 days (515±147s vs. 330±136s, p=0.00001) compared to baseline. OT was similar at 
hospital discharge and at 30 days’ follow-up (536±195s vs. 515±147s, p=0.695). 
 
Distribution and change in lysis time 
The distribution of LT at the 4 time points is shown in Figure 2. Baseline LT was positively 
skewed and many patients exhibited impaired endogenous thrombolysis with prolonged lysis 
times. LT was significantly reduced after GPI/UFH compared to baseline (median[IQR] 747 
[579-950] s vs. 1075 [882-1682] s, p=0.00001). LT was similar at hospital discharge (1172 [931-
2202] s vs. 1075 [882-1682] s, p=0.321), and at 30 days’ follow-up (1059 [806-1569] s vs. 1075 
[882-1682] s, p=0.801) compared to baseline [Figure 3-B]. At 30 days, LT was similar to LT at 
hospital discharge (1059 [806-1569] s vs. 1172 [931-2202] s, p=0.112).  
 
Recurrent adverse clinical events and OT and LT 
There were a total of 13 MACE events experienced by 13 patients, namely 8 CVD, 3 nonfatal 
MI (of which 1 attributable to acute stent thrombosis within 24 hours and 1 attributable to 
late stent thrombosis at 76 days), and 2 ischaemic strokes (not associated with atrial 
fibrillation). There were a total of 2 major bleeding events (BARC type 3a). There were no 
reported non-compliance issues with antiplatelet medication in those patients who 
experienced an adverse event. 
Patients who went on to experience a MACE event, demonstrated a baseline OT that was 
significantly shorter (more thrombotic) than the OT of patients who did not experience an 
adverse event (253±150s vs. 354±134s; p=0.017), particularly with respect to nonfatal MI (OT 
135±45s vs. 346±137s; p=0.009), and ischaemic stroke (OT 133±31s vs. 343±138s; p=0.036) 
[Figure 4]. Baseline OT did not differ between patients who experienced a major bleed and 
those who did not (297±121s vs. 339±141s; p=0.682), but the number of events was small. 
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ROC curve analysis showed that no particular threshold of baseline OT was a good binary 
discriminator of MACE risk [Figure 5-A]. Survival analysis demonstrated no relationship 
between baseline OT and MACE (hazard ratio [HR]: 0.99, 95%CI:0.989-0.999) or major 
bleeding. At other pre-specified time points, OT was not related to MACE or major bleeding. 
Baseline LT level significantly discriminated between patients with and without MACE, with 
an area under the ROC curve of 0.59 (95% confidence interval [CI]:0.471-0.693; p<0.05) 
[Figure 5-B]. LT≥2901s was the optimal cut-point to predict MACE (rounded to 3000s for 
clinical ease), with sensitivity 31% and specificity 89% [Figure 5-B]. There were no LT readings 
between 2900s and 3000s that could have been wrongly classified based on rounding the cut-
point to 3000s. Survival analysis demonstrated that LT≥3000s at baseline was strongly related 
to MACE (HR:3.31, 95%CI:1.02-10.78, p=0.045) [Figure 6], driven by CVD (HR:4.17, 
95%CI:0.99-17.51, p=0.05) [Figure 7-B and Table 5]. LT≥3000s at baseline was not related to 
an increase in major bleeding, but the number of events was small. LT at the other pre-
specified time points was not related to MACE or major bleeding. 
 
Spontaneous coronary reperfusion and ST-resolution 
Five STEMI patients had spontaneous coronary reperfusion, defined as complete or partial 
resolution of ST-elevation and chest pain before PPCI. All five patients had short baseline LT 
(<1000s), TIMI-3 flow at presentation, and uneventful 12-month outcomes. Lysis time was 
inversely correlated with spontaneous coronary reperfusion before PPCI (r= -0.3, p=0.022). 
The baseline OT in those with spontaneous coronary perfusion was no different to those 
patients without spontaneous coronary reperfusion (306±156s vs. 340±140s, p=0.609). 
 
Influence of patient characteristics on OT and LT and outcomes 
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There was a weak positive correlation between baseline OT and the time from symptom onset 
(r=0.2, p=0.04) but no relationship between baseline LT and time from symptom onset. The 
following variables were interrogated (using parametric or non-parametric tests, as 
appropriate) for effects on baseline OT and LT: all patient characteristics in Table 2; 
haematological and biochemical profiles on admission in Table 3; the echocardiographic, 
angiographic, and interventional characteristics in Table 4. Smokers exhibited a shorter (more 
thrombotic) OT than non-smokers (294±105s vs. 365±153s, p=0.026). There was a weak 
negative correlation between baseline OT and creatinine level on admission (r= -0.4, 
p=0.057), and a weak positive correlation between baseline OT and pre-PCI TIMI-3 flow (r=0.2, 
p=0.063). None of the other variables including haematocrit, platelet count, troponin I, or left 
ventricular function correlated with baseline OT or LT. Female sex and patients with raised 
creatinine level on admission had significantly more baseline LT≥3000s values measured 
[Table 2 and Table 3]. Of the characteristics in Tables 2 and 3, only the following were related 
to MACE: increasing age (p=0.008), statin therapy (p=0.012), prior aspirin use (p=0.001), beta-
blocker treatment (p=0.024), angiotensin-converting enzyme (ACE) inhibitor treatment 
(p=0.0008), calcium antagonists (p=0.001), prior renal insufficiency (p=0.002), high serum 
creatinine (p=0.001), and right coronary artery culprit vessel (p=0.020). None of the variables 
were related to major bleeding outcome, but the number of events was small. 
The following variables were then entered into the final baseline multivariate Cox 
proportional hazard model: age (HR:1.07, 95%CI:1.02-1.13, p=0.005), statin therapy (HR:6.39, 
95%CI:1.95-20.99, p=0.002), and two traditional risk factors, namely diabetes (HR:0.51, 
95%CI:0.15-1.71, p=0.276) and hypertension (HR:0.51, 95%CI:0.16-1.60, p=0.246). None of 
these basic covariates were correlated either with LT or its dichotomized version, such as sex, 
which would have increased the standard error of the HR in the Cox proportional hazard 
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model. We did not include prior aspirin use in the model, as although in our small sample it 
was not related to OT or LT, we felt biologically it was likely to have influenced baseline 
platelet reactivity and thus not a truly independent variable. Multivariate analysis including 
the baseline covariates showed that baseline LT≥3000s remained strongly related to MACE 
after adjustment for risk factors (HR:4.26, 95%CI:1.13-16.01, p=0.032). Net reclassification 
improvement (NRI) showed that the inclusion of baseline LT≥3000s in a model containing 
three baseline predictors (age, statin therapy and diabetes) significantly added to the model 
effectiveness (NRI estimate 0.347, p=0.018). 
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Discussion 
Impaired (prolonged) endogenous thrombolysis, seen in 13% STEMI patients at presentation, 
prior to PPCI, was predictive of an increased risk of adverse cardiovascular events, in 
particular cardiovascular death. Enhanced (rapid) endogenous thrombolysis was seen in 
patients with STEMI who demonstrated spontaneous coronary reperfusion, with 
spontaneous ST-segment resolution and TIMI-3 flow prior to intervention. Enhanced platelet 
reactivity, as demonstrated by short OT, was seen in patients with recurrent adverse events 
of nonfatal MI and stroke. Whilst the treatment with DAPT and PPCI, and the patient journey 
over time, resulted in OT prolongation; LT was similar pre-PPCI, at 30 days’ follow-up and at 
hospital discharge. This would suggest that LT could be tested at any point up to 30 days, 
provided GPI is not used, and would not need to necessarily be tested prior to PPCI. However, 
although overall LT was similar at these time-points, only LT pre-PPCI was predictive of 
adverse cardiovascular events. This may at least in part be explained by the fact that many 
events occurred in the first 30 days [Figure 6] and that the “tail” of LT distribution, where 
some patients exhibited LT>6000s, was no longer apparent at 30 days. The AUC although 
significant, is overall small and while LT as a predictor of MACE is highly specific, its sensitivity 
is low, such that LT on its own is not a very good independent predictor of events. This may 
be better assessed in a larger study with a broad spectrum of patients which would avoid bias 
and allow for control of confounders, as well as allow calculation of the additive value of LT 
to other predictive markers in the assessment of LT performance as an additional predictive 
test. 
It would seem that antiplatelet medications favourably alter (prolong) OT to reduce platelet 
reactivity over time, but LT is unaffected by standard chronic pharmacological treatment and 
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coronary intervention. However, in the acute phase, administration of GPI results in marked 
prolongation of OT and reduction in LT, an effect that wears off by the time the patient leaves 
the hospital, when LT has returned to baseline. 
Prior work has shown that aspirin at low doses does not alter LT. More potent antiplatelet 
agents such as clopidogrel have negligible effects on LT (21). In patients with atrial fibrillation, 
the administration of non-vitamin K antagonist oral anticoagulants (NOACs), but not warfarin, 
favourably modulates (reduces) LT (22, 23). Previously in a study of patients with coronary 
disease, treatment with the PAR1 inhibitor vorapaxar resulted in reduction of LT (24). Our 
current work lends further support to the notion that agents that inhibit thrombin, but not 
antiplatelet agents, can exert a favourable effect on endogenous thrombolysis. This may 
underlie the observed findings of adding NOACs on top of standard dual antiplatelet in 
patients with ACS, where in APPRAISE-2, RE-DEEM, and ATLAS ACS 2–TIMI 51 trials, a 
reduction in recurrent ischaemic events was observed when a NOAC was used (25-27). 
Our data are supported by prior studies which have demonstrated that impaired endogenous 
thrombolysis is a risk factor for adverse cardiac events in a number of patient cohorts, 
including non-ST-elevation MI (13), end-stage renal failure (14), stroke (28) and diabetes (29). 
The cut-point of LT that predicts MACE appears to be consistent in our study and prior studies 
(13, 14). Furthermore, D-dimer levels on admission were associated with a higher incidence 
of no reflow (30) and higher risk of MACE in STEMI patients undergoing PPCI (31) and elevated 
levels post-PPCI were related to impairment of myocardial function (32). Furthermore, when 
intracoronary thrombi aspirated during PPCI were examined, increased von Willebrand 
factor, P-selectin and fibrin content were related to unfavourable thrombus characteristics 
rendering the thrombus resistant to lytic therapy (33) and denser plasma fibrin clots were 
independently associated with high fibrin content (34). Recently, a crucial role of fibrinolysis 
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in determining infarct outcome was shown by combined inhibition of thrombin-activatable 
fibrinolysis inhibitor and plasminogen activator inhibitor-1, prior to transient cerebral artery 
occlusion in mice, which reduced cerebral infarct size by 50% (35).  
Baseline LT≥3000s was more commonly seen in females in our study, and data show that 
women with STEMI tend to have a higher mortality than men, despite PPCI, and this is likely 
to be at least in part attributable to a worse risk profile (36-38). An earlier report assessing 
global thrombotic status showed no difference in LT between male and female healthy 
volunteers (39), thus whether the excess risk in women with STEMI may in part be related to 
worse thrombolytic status in the setting of STEMI, requires further study.  
Others have shown that high residual platelet reactivity (HRPR) on DAPT as assessed with 
the VerifyNow technique was predictive of recurrent events, especially in ACS patients 
undergoing PCI (40, 41). However, those tests were uniformly performed on therapeutic 
DAPT, whereas our initial sample was performed before therapeutic levels of DAPT had 
been achieved, and our third sample was done at follow up, when almost all events had 
occurred. It would have been the pre-discharge sample that we would have expected to 
correlate with MACE. The discrepancy between earlier findings of HRPR and our results can 
be explained by the different techniques used. ADP-induced platelet aggregation 
(VerifyNow) is more sensitive than the GTT in detecting ADP antagonist effect. ADP-induced 
platelet aggregation measurement is based on the concept that ADP plays a crucial role in 
platelet aggregation and thrombus formation. The GTT measures thrombus formation at 
high shear stress.  However, there is strong evidence that platelet aggregation induced by 
high shear (relevant to arterial shear rates in vivo) occurs independently of ADP (42, 43), 
which explains the lower sensitivity of GTT technique to ADP antagonism. The fact that ADP 
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mediated thrombus formation does not underlie all arterial thrombotic events also helps 
explain the low specificity (53%) reported with the Verify Now technique (44) and may 
support the validity of our results. The lower specificity of HRPR as measured by VerifyNow 
compared with LT measurement is further supported by emerging evidence showing the 
important role of P2Y12 receptor signalling not in the growth rate but in the stability of the 
evolving thrombus. This effect can be measured by detecting disaggregation of ADP-induced 
aggregates and low disaggregation identified patients on clopidogrel at risk of MI with equal 
or better specificity than did the VerifyNow (45). The concept that alteration of thrombus 
stability plays a major role in the mechanism of the antithrombotic effect of antiplatelet 
medication is gaining momentum (46). 
The main limitation of our study is the small sample size. As such, this data is hypothesis 
generating and requires validation in suitably powered, large, prospective clinical study. In 
addition, because of the need to consent patients pre-procedure, we excluded those who 
were in extremis, such as those with cardiogenic shock or out-of-hospital cardiac arrest, who 
were at very high risk of MACE and who may have had even worse thrombotic profile than 
the patients studied. Another limitation is that optimal antithrombotic medication in the 
context of STEMI comprises of aspirin combined with newer P2Y12 inhibitors, namely 
ticagrelor or prasugrel. Whilst these medications are increasingly used, in much of the UK 
and elsewhere, clopidogrel and aspirin administration in the ambulance remains the 
“standard of care” due to financial constraints. It is unlikely that prasugrel or ticagrelor 
administration would have impacted on endogenous thrombolysis, but assessment of the 
effect of these newer and more potent antiplatelet medications would have been desirable. 
The study could not assess the relationship between thrombotic status and bleeding events, 
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since the number of bleeds was very small, probably helped by the majority (>90%) of 
interventions being performed radially. Furthermore, the timing of the first (baseline) 
sample was such that absorption of antiplatelet agents was unreliable and therapeutic 
doses were likely not have been reached. Although this may be a criticism of our study, it 
also reflects real-time thrombotic status at the time of PPCI. 
For the first time, we show that impaired endogenous thrombolysis in STEMI patients is 
predictive of a high risk of adverse events despite good angiographic outcome, whilst patients 
with spontaneous coronary reperfusion and ST-segment resolution demonstrate enhanced 
(short) endogenous thrombolysis. Large clinical studies are needed to see if the addition of 
potent antithrombotic medications such as NOACs to standard care with DAPT in those with 
impaired endogenous thrombolysis, can reduce adverse events. The GTT may serve as a risk 
stratification tool to identify patients with impaired endogenous thrombolysis, and to target 
those who are most pro-thrombotic with selective escalation of antithrombotic medication, 
whether to further target platelets or thrombin; and to avoid excessive unnecessary 
antithrombotic agents in those who are at low risk.  
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What is known on this topic 
• The outcome of a thrombotic event depends on the balance between prothrombotic 
drivers and the effectiveness of the intrinsic endogenous thrombolytic potential. 
• Contemporary antithrombotic and antiplatelet agents, whilst reducing recurrent 
thrombosis, have significantly increased the risk of bleeding.  
• Identification of patients at high-risk of future thrombotic complications would be 
highly desirable, since this group could be targeted with more potent antithrombotic 
medications, allowing use of less potent agents (thereby reducing bleeding risk) in 
lower risk groups.  
 
What this paper adds 
• in patients with STEMI presenting for PPCI, impaired endogenous thrombolysis, as 
measured in the catheterisation laboratory with the point-of-care Global Thrombosis 
Test, is predictive of recurrent adverse. 
• Patients with STEMI who demonstrate spontaneous reperfusion and spontaneous ST-
segment resolution have enhanced (rapid) endogenous thrombolysis.  
• Endogenous thrombolysis may be a novel target for pharmacological intervention in 
STEMI, and allow targeting of potent antithrombotic medications to high-risk patients.  
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Figure legends 
 
Figure 1: Distribution of Occlusion Time at 4 time-points 
(A) Baseline, upon admission and before PPCI, (B) after administration of glyocoprotein IIb/IIIa 
inhibitor (GPI), (C) at clinical stabilisation and just prior to hospital discharge, and (D) at 30-days post 
hospitalisation. OT=occlusion time. Y axis shows % patients. 
 
Figure 2: Distribution of Lysis Time at 4 time-points  
(A) Baseline, upon admission and before PPCI, (B) after administration of glyocoprotein IIb/IIIa 
inhibitor (GPI), (C) at clinical stabilisation and just prior to hospital discharge, and (D) at 30-days post 
hospitalisation. LT=occlusion time. Y axis shows % patients. 
 
Figure 3: Occlusion Time and Lysis Time  (mean ± SD)  
Occlusion time (OT) was prolonged after treatment with glyocoprotein IIb/IIIa inhibitor 
(GPI)/unfractionated heparin (UFH) or after bivalirudin (Bival)/UFH, at discharge from hospital, and at 
30 days post hospitalisation compared to baseline OT. Lysis time (LT) was shorter after GPI/UFH than 
at baseline. *p<0.05, compared to baseline. 
 
Figure 4: MACE and major bleeding according to baseline Occlusion Time 
Baseline OT in patients who did not have an adverse outcome is indicated by open bars; baseline OT 
in patients who had an adverse outcome is indicated by solid bars. *p<0.05. 
MI = myocardial infarction; CVA = cerebrovascular accident; CVD = cardiovascular death 
 
Figure 5: ROC curves for baseline Occlusion Time and Lysis Time 
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Receiver-operating characteristic (ROC) curves for (A) occlusion time (OT), and (B) lysis time (LT) at 
baseline. An LT≥3000s was identified as the optimal cut point to predict MACE outcome, with 
sensitivity of 31% and specificity of 89%. 
 
 
Figure 6: Probability of event-free survival according to baseline LT 
Kaplan-Meier curves showing probability of event-free survival (survival free of MACE) in STEMI 
patients based on the baseline LT. An LT≥3000s at baseline was associated with a hazard ratio of 3.31. 
Solid line indicates LT<3000s and dotted line indicates LT≥3000s. 
 
Figure 7: Major adverse cardiovascular events and major bleeding according to baseline LT 
(A) Baseline LT in patients who did not have an outcome is indicated by open bars; baseline in patients 
who had an outcome is indicated by solid bars, (B) Baseline LT<3000s is indicated by open bars; 
baseline LT≥3000s is indicated by solid bars. *p<0.05. †p=0.05. 
MI = myocardial infarction; CVA = cerebrovascular accident; CVD=cardiovascular death. 
 
Figure 8: HR for major adverse cardiovascular events according to baseline LT 
Hazard ratios (HR) for cardiovascular death (CVD), nonfatal myocardial infarction (MI), and stroke 
according to baseline lysis time (LT). The 95% confidence interval is shown in brackets. n: number of 
patients. *p<0.05.  
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Table 1: Exclusion Criteria 
Inability to consent 
Current participation in another study 
Less than 18 years of age 
Known diagnosis of malignancy 
Sepsis 
Bleeding diathesis 
Thrombolysis, warfarin, heparin, or GPI inhibitor treatment before sampling 
Blood dyscrasia (platelets <100x109/L, haemoglobin <80g/L, international normalized ratio 
>1.4, activated partial thromboplastin time more than twice upper limit of normal, 
leukocyte count <3.5x109/L, neutrophil count <1x109/L) 
Intolerance or contraindication to aspirin or clopidogrel 
Complete follow-up over 1-year period not likely 
Life expectancy <12 months due to known non-cardiovascular condition 
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Table 2: Baseline Patient Characteristics 
 
 
Overall Group 
(n=82) 
Baseline LT         
<3000s 
(n=71) 
Baseline LT           
≥3000s 
(n=11) 
p Value 
Age, yrs 63±12 63±12  64±10 0.444 
Male  67 (81.7) 61 (85.9) 6 (54.5) 0.025 
Diabetes mellitus  13 (15.9) 12 (16.9) 1 (9.1) 1.000 
Active smoker 31 (37.8) 29 (40.8) 2 (18.2) 0.193 
Hypertension  39 (47.6) 33 (46.5) 6 (54.5) 0.749 
Prior CAD  12 (14.6) 10 (14.1) 2 (18.2) 0.660 
Renal insufficiency  4 (4.9) 2 (2.8) 2 (18.2) 0.085 
PVD  2 (2.4) 2 (2.8) 0 1.000 
Prior CVA  1 (1.2) 1 (1.4) 0 1.000 
Prior aspirin use  15 (18.3) 12 (16.9) 3 (27.3) 0.414 
Medications on discharge     
Aspirin  80 (97.6) 70 (98.6) 10 (90.9) 0.252 
Clopidogrel 79 (96.3) 69 (97.2) 10 (90.9) 0.355 
VKA 4 (4.9) 4 (5.6) 0 1.000 
Beta-blocker  64 (78.1) 56 (78.9) 8 (72.7) 0.699 
ACE inhibitor  68 (82.9) 61 (85.9) 7 (63.6) 0.087 
Calcium antagonists  12 (14.6) 9 (12.7) 3 (27.3) 0.199 
Statin  69 (84.2) 61 (85.9) 8 (72.7) 0.369 
Nitrate  9 (11.0) 8 (11.3) 1 (9.1) 1.000 
Insulin  5 (6.1) 4 (5.6) 1 (9.1) 0.523 
Metformin  5 (6.1) 5 (7.0) 0 1.000 
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Values are mean ± standard deviation or n (%). Renal insufficiency was defined by creatinine levels 
>177 µmol/L (13). Prior aspirin use was defined as aspirin use before hospitalisation. 
ACE: angiotensin-converting enzyme, CAD: coronary artery disease, CVA: cerebrovascular accident, 
LT: lysis time, PVD: peripheral vascular disease, VKA: vitamin K antagonist. 
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Table 3: Blood Tests on Admission 
 Overall Group 
(n=82) 
Baseline LT  
<3000s 
(n=71) 
Baseline LT 
≥3000s 
(n=11) 
p value 
Haemoglobin (g/L) 139±20 140±19 130±27 0.115 
Haematocrit (%) 42±6 42±6 39±6 0.077 
Platelet count (x 109/L) 257±71 253±70 286±72 0.154 
Creatinine (µmol/L)   94±39 91±29 117±76 0.039 
C-reactive protein (mg/L) 13±20 13±18 17±30 0.571 
Troponin T (ng/L), peak at 12 hrs 20,200±2770 21,300±2850 9,800±1670 0.336 
Total Cholesterol (mmol/L) 4.8±1.2 4.8±1.2 4.9±1.2 0.711 
 
Values are mean ± standard deviation. 
Normal values: haemoglobin 130-180 g/L in adult males and 115-165 g/L in adult females; haematocrit 
40-52 % in adult males and 36-47 % in adult females; platelet count 150-400 x109/L; creatinine 60-110 
μmol/L in adult males and 45-90 μmol/L in adult females; C-reactive protein 0-5 mg/L; troponin T <14 
ng/L; total cholesterol ≤4.0 mmol/L.   
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Table 4: Angiographic, Interventional, and Echocardiographic Patient Characteristics 
 Overall Group 
(n=82) 
Baseline LT  
<3000s 
(n=71) 
Baseline LT  
≥3000s 
(n=11) 
p value 
1-vessel disease  43 (52.4) 39 (54.9) 4 (36.4) 0.260 
2-vessel disease  22 (26.8) 17 (23.9) 5 (45.5) 0.141 
3-vessel disease  16 (19.5) 14 (19.7) 2 (18.2) 0.902 
Culprit vessel      
          LAD 25 (30.9) 24 (33.8) 1 (9.1) 0.131 
          Diagonal  2 (2.5) 2 (2.8) 0 0.901 
          LCA 9 (11.1) 6 (8.5) 3 (27.3) 0.080 
          OM 3 (3.7) 3 (4.2) 0 0.923 
          RCA 42 (51.9) 35 (49.3) 7 (63.6) 0.381 
GPI use  58 (70.7) 52 (73.2) 6 (54.5) 0.285 
Bivalirudin use  4 (4.9) 3 (4.2) 1 (9.1) 0.444 
Balloon predilatation  57 (69.5) 49 (69.0) 8 (72.7) 1.000 
Stent implantation      
          BMS 19 (24.4) 15 (21.1) 4 (36.4) 0.273 
          DES 59 (75.6) 52 (73.2) 7 (63.6) 0.514 
TIMI-3 flow      
          Before PCI 14 (17.5) 13 (18.3) 1 (9.1) 0.461 
          After PCI 69 (86.3) 59 (83.1) 10 (90.9) 0.520 
LV function after index event     
          Normal (EF ≥ 55%) 45 (59.2) 37 (52.1) 8 (72.7) 0.212 
          Mildly impaired (EF 45-54%) 17 (22.4) 16 (22.5) 1 (9.1) 0.333 
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          Moderately impaired (EF 36-44%) 13 (17.1) 13 (18.3) 0 0.264 
          Severely impaired (EF ≤ 35%) 1 (1.3) 1 (1.4) 0 0.673 
Door to balloon time, min 24±16 23±16 26±14 0.519 
Call to balloon time, min 100±18 100±19 98±14 0.940 
 
Values are n (%).  
BMS: bare metal stent, DES: drug eluting stent, EF: ejection fraction, GPI: glycoprotein IIb/IIIa inhibitor, 
LAD: left anterior descending coronary artery, LCA: left circumflex coronary artery, LT: lysis time, LV: 
left ventricular, OM: obtuse marginal coronary artery, PCI: percutaneous coronary intervention, RCA: 
right coronary artery, TIMI: Thrombolysis in Myocardial Infarction. 
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Table 5: Clinical outcome at 12 months’ follow-up 
 Overall Group 
(n=82) 
Baseline LT 
<3000 s 
(n=71) 
Baseline LT 
≥3000 s 
(n=11) 
HR (95% CI) p value 
Cardiovascular death, 
nonfatal MI, and stroke 
13 (15.9) 9 (12.7) 4 (36.4) 3.31 (1.02-10.78) 0.047 
Cardiovascular death* 8 (9.8) 5 (7.0) 3 (27.3) 4.18 (0.99-17.51) 0.05 
Nonfatal MI 3 (3.7) 2 (2.8) 1 (9.1) 3.96 (0.36-43.94) 0.263 
Stroke** 2 (2.4) 2 (2.8) 0 NA NA 
Major bleeding 2 (2.4) 1 (1.4) 1 (9.1) 8.79 (0.55-140.46) 0.124 
 
Values are n (%).  
CI: confidence interval, HR: hazard ratio, LT: lysis time, MI: myocardial infarction, NA: not applicable. 
* Cardiovascular deaths defined as death in the presence of acute coronary syndrome, significant 
cardiac arrhythmia, or refractory congestive heart failure, or death attributed to cardiovascular cause 
at post-mortem.   
** Causes of stroke were ischaemic stroke.  
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